Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06235151 · ClinicalTrials.gov registry record · Phase 3

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

A Phase 3 study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Curium US.

Recruiting
Registry status
Phase 3
Development phase
439
Enrollment target
20
Study locations

NCT06235151 is a Phase 3 study of Prostate Cancer and Prostate Adenocarcinoma that is actively recruiting participants, run by Curium US. The registered enrollment target is 439 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06235151, a Phase 3 study of Prostate Cancer and Prostate Adenocarcinoma, is actively recruiting participants, sponsored by Curium US.

RECRUITING
Registry status
Phase 3
Development phase
439 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Conditions Studied

Prostate Cancer Prostate Adenocarcinoma

Interventions

  • DRUG Copper Cu 64 PSMA I&T

Study Locations (20)

California

  • Providence Medical Foundation - Fullerton
  • Tower Urology - Los Angeles
  • VA Greater Los Angeles Healthcare System - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Newport Beach
  • University of California, Irvine - Orange
  • San Francisco VA Medical Center - San Francisco
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
  • Providence Saint John's Health Center - Santa Monica
  • Stanford Hospital & Clinics - Stanford

Florida

  • University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center - Miami
  • CIRA Health - Miami
  • Sarasota Memorial Health Care System - Sarasota
  • Florida Urology Partners - Tampa

Indiana

  • Urology of Indiana, LLC - Carmel
  • IU Health Neuroscience Center - Indianapolis

Arkansas

  • Arkansas Urology - Little Rock

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Illinois

  • Edward Hines Jr. VA Hospital - Hines

Iowa

  • University of Iowa - Iowa City

Kansas

  • The University of Kansas Hospital - Kansas City

Trial Details

FieldValue
Enrollment Target 439 participants
Start Date 2024-04-01
Est. Completion 2026-03
Phase Phase 3

Sponsor

Curium US

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06235151

The ClinicalTrials.gov registry entry for NCT06235151 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 439 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (28% lower). The listed sponsor is Curium US, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Copper Cu 64 PSMA I&T is the first listed.

NCT06235151 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT06235151 about?

NCT06235151 is a clinical study titled "Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer". This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

What is the current status of trial NCT06235151?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 439 participants. The study started on 2024-04-01. Estimated completion is 2026-03.

What conditions does trial NCT06235151 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma.

What interventions are being tested in trial NCT06235151?

The interventions under investigation include: Copper Cu 64 PSMA I&T (DRUG).

Who is sponsoring clinical trial NCT06235151?

This trial is sponsored by Curium US, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06235151 being conducted?

This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Prostate Adenocarcinoma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.